Reuters logo
BRIEF-Uniqure announces AMT-061 to enter pivotal study in 2018
October 19, 2017 / 11:14 AM / in a month

BRIEF-Uniqure announces AMT-061 to enter pivotal study in 2018

Oct 19 (Reuters) - Uniqure Nv

* Uniqure announces Hemophilia B gene therapy program to enter pivotal study with FIX-Padua variant in 2018

* Uniqure NV - ‍plans to initiate pivotal study with enhanced AMT-061 in 2018​

* Uniqure nv - ‍acquired patent family that covers FIX-Padua variant and its use in gene therapy for treatment of Coagulopathies, including Hemophilia B​

* Uniqure - ‍FDA agreed AMT-061 will be included under existing breakthrough therapy designation and IND for AMT-060​

* Uniqure NV - ‍EMA also has agreed that AMT-061 will be included under current prime designation​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below